G1 Therapeutics, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the COSELA Approval Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
It is now my pleasure to turn the call over to your host for today, Mr. Will Roberts. Sir, the floor is yours.
Thank you, Sylvia. Good morning, everyone, and welcome to the G1 conference call to discuss the approval of COSELA, the brand name for trilaciclib, which was approved by the U.S. Food and Drug Administration late on Friday, February 12 to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
The press release issued Friday evening is available on our corporate website and contains the indication statement for COSELA as well as important safety information. The full U.S. prescribing information for COSELA is available on our corporate website and on our brand
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
